甲磺酸艾日布林是一种抗肿瘤药物，可用于治疗转移性乳腺癌患者。
Eribulin (1-100 nM; 72 h) inhibits cells proliferation, with IC 50 s of 22.8 and 21.5 nM for LM8 and Dunn cells, respectively. Eribulin (10-50 nM; 12-72 h) increases early apoptosis significantly after 24 h treatment at the dose of 50 nM in LM8 cells. Eribulin (10-50 nM; 12-72 h) induces G2/M arrest by 12 h treatment with at the dose of 50 nM, but not by long-term treatment (72 h) with 10 nM in LM8 cells. Eribulin (1-50 nM; 12 h) does not induce senescence in LM8 cells. Eribulin (1-10 nM; 16 h) induces morphological change and suppresses cell migration in a low concentration in LM8 cells.
Cell Proliferation Assay
Apoptosis Analysis
Cell Cycle Analysis
Eribulin (1 mg/kg; i.v. once a week for 2 weeks) reduces primary tumor growth and lung metastasis of osteosarcoma in mice. Eribulin (1 mg/kg; once i.v.) suppresses circulating tumor cells (CTC) appearance in the low-concentration phase.